Home › Chronic-Phase Myeloid Leukemia › California
Pag-aaral pangklinika para sa Chronic-Phase Myeloid Leukemia sa California
5 pag-aaral para sa Chronic-Phase Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa California.
Opisyal na teksto ng pag-aaral (English)
Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1062, Duarte
- Ascentage Investigative Site #1099, Irvine
- Ascentage Investigative Site #1075, La Jolla
- at 4 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT06423911A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07020533A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
- Stockton Hematology Oncology Medical Group Inc, Stockton
- Lundquist Inst BioMed at Harbor, Torrance
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT07091019Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 10, 2026 · NCT06229860A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
- UC Irvine Health, Orange
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 12, 2026 · NCT06163430Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.